Insider Buying: NewGenIvf Group (NASDAQ:NIVF) Director Purchases $2,500,000.00 in Stock

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung purchased 2,500,000 shares of NewGenIvf Group stock in a transaction that occurred on Monday, July 27th. The stock was acquired at an average price of $1.00 per share, for a total transaction of $2,500,000.00. Following the transaction, the director directly owned 3,722,223 shares of the company’s stock, valued at $3,722,223. The trade was a 204.55% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Kong Yiu Cheung also recently made the following trade(s):

• On Thursday, June 18th, Kong Yiu Cheung acquired 500,000 shares of NewGenIvf Group stock. The stock was acquired at an average cost of $1.33 per share, with a total value of $665,000.00.

NewGenIvf Group Price Performance

Shares of NASDAQ:NIVF opened at $1.14 on Friday. The firm has a fifty day simple moving average of $2.71 and a two-hundred day simple moving average of $10.90. NewGenIvf Group Limited has a 52 week low of $1.11 and a 52 week high of $1,539.00. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.12 and a quick ratio of 2.98.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wall Street Zen raised NewGenIvf Group to a “hold” rating in a research note on Saturday, July 4th. Weiss Ratings reiterated a “sell (d)” rating on shares of NewGenIvf Group in a report on Friday, July 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, NewGenIvf Group has an average rating of “Sell”.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.